Bayer Long Term Debt 2010-2024 | BAYRY
Bayer long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
- Bayer long term debt for the quarter ending September 30, 2024 was $40.325B, a 5.52% increase year-over-year.
- Bayer long term debt for 2023 was $41.318B, a 16.05% increase from 2022.
- Bayer long term debt for 2022 was $35.602B, a 17.51% decline from 2021.
- Bayer long term debt for 2021 was $43.161B, a 13.82% increase from 2020.
Bayer Annual Long Term Debt
(Millions of US $) |
| 2023 |
$41,318 |
| 2022 |
$35,602 |
| 2021 |
$43,161 |
| 2020 |
$37,920 |
| 2019 |
$41,341 |
| 2018 |
$44,538 |
| 2017 |
$14,110 |
| 2016 |
$17,905 |
| 2015 |
$18,336 |
| 2014 |
$24,571 |
| 2013 |
$7,425 |
| 2012 |
$8,954 |
| 2011 |
$10,705 |
| 2010 |
$13,205 |
| 2009 |
$15,982 |
Bayer Quarterly Long Term Debt
(Millions of US $) |
| 2024-09-30 |
$40,325 |
| 2024-06-30 |
$40,273 |
| 2024-03-31 |
$41,242 |
| 2023-12-31 |
$41,318 |
| 2023-09-30 |
$38,215 |
| 2023-06-30 |
$39,862 |
| 2023-03-31 |
$36,035 |
| 2022-12-31 |
$35,602 |
| 2022-09-30 |
$39,744 |
| 2022-06-30 |
$40,505 |
| 2022-03-31 |
$41,126 |
| 2021-12-31 |
$43,161 |
| 2021-09-30 |
$43,600 |
| 2021-06-30 |
$44,176 |
| 2021-03-31 |
$45,714 |
| 2020-12-31 |
$37,920 |
| 2020-09-30 |
$41,137 |
| 2020-06-30 |
$37,379 |
| 2020-03-31 |
$40,611 |
| 2019-12-31 |
$41,341 |
| 2019-09-30 |
$41,991 |
| 2019-06-30 |
$41,277 |
| 2019-03-31 |
$43,105 |
| 2018-12-31 |
$44,538 |
| 2018-09-30 |
$46,924 |
| 2018-06-30 |
$50,796 |
| 2018-03-31 |
$15,086 |
| 2017-12-31 |
$14,110 |
| 2017-09-30 |
$19,410 |
| 2017-06-30 |
$15,583 |
| 2017-03-31 |
$18,244 |
| 2016-12-31 |
$17,905 |
| 2016-09-30 |
$18,431 |
| 2016-06-30 |
$18,625 |
| 2016-03-31 |
$18,886 |
| 2015-12-31 |
$18,336 |
| 2015-09-30 |
$18,625 |
| 2015-06-30 |
$19,002 |
| 2015-03-31 |
$19,099 |
| 2014-12-31 |
$24,571 |
| 2014-09-30 |
$15,129 |
| 2014-06-30 |
$10,985 |
| 2014-03-31 |
$11,104 |
| 2013-12-31 |
$7,425 |
| 2013-09-30 |
$7,685 |
| 2013-06-30 |
$9,541 |
| 2013-03-31 |
$9,030 |
| 2012-12-31 |
$8,954 |
| 2012-09-30 |
$8,906 |
| 2012-06-30 |
$9,407 |
| 2012-03-31 |
$10,390 |
| 2011-12-31 |
$10,705 |
| 2011-09-30 |
$10,649 |
| 2011-06-30 |
$10,433 |
| 2011-03-31 |
$13,039 |
| 2010-12-31 |
$13,205 |
| 2010-09-30 |
$13,376 |
| 2010-06-30 |
$14,089 |
| 2010-03-31 |
$14,791 |
| 2009-12-31 |
$15,982 |
| 2009-09-30 |
$16,757 |
| 2009-06-30 |
$16,120 |
| 2009-03-31 |
$16,659 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$19.295B |
$51.553B |
|
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
|
